Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.
暂无分享，去创建一个
P. Richardson | P. Moreau | Jianchang Lin | T. Masszi | M. Hansson | M. Mateos | P. Gimsing | A. Stoppa | M. Hamadani | L. Pour | D. Berg | I. Sandhu | S. Jackson | H. Velde | N. Grzasko | L. Viterbo | G. Borsaru